摘要：Treatment of relapsed/refractory T-cell lymphomas represents an unmet medical need. We here analyze the results of two studies, one prospective and one retrospective, re- cently published in order to evaluate the therapeutic impact of bendamustine in this set- ting of diseases. Overall 80 adult patients, the majority with a diagnosis of systemic nodal peripheral T-cell lymphoma were treated with bendamustine monotherapy. Overall re- sponse rate was achieved in nearly 50% of patients with some complete responses; an- gioimmunoblastic T-cell lymphoma appeared the hystotype most responsive to benda- mustine, which however showed activity also in some cases of cutaneous T-cell lympho- mas and prolymphocytic leukemia. Patients' compliance to treatment was generally good. Bendamustine deserves further investigation in patients with T-cell lymphomas
